FIELD: medicine, phthisiology. SUBSTANCE: invention relates to drugs containing organic active components. Invention proposes to use 2,4-dioxo-5-fluoropyrimidine (fluorouracil) as a tuberculostatic agent that belongs to an antimetabolite group of cytostatic agents. EFFECT: broadened assortment of tuberculostatic agents. 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
TUBERCULOSTAT AGENT | 2001 |
|
RU2185170C1 |
METHOD FOR TREATING THE CASES OF EXPERIMENTAL TUBERCULOSIS | 2000 |
|
RU2165761C1 |
TUBERCULOSTATIC AGENT | 2002 |
|
RU2207126C1 |
ANTI-TUBERCULOSIS PREPARATION | 2002 |
|
RU2211035C1 |
METHOD FOR TREATING THE CASES OF TUBERCULOSIS | 2002 |
|
RU2212240C1 |
METHOD OF TREATMENT OF EXPERIMENTAL TUBERCULOSIS | 2001 |
|
RU2207127C1 |
METHOD OF TREATING PULMONARY TUBERCULOSIS FEATURING PREDOMINANTLY EXUDATIVE TYPE OF INFLAMMATION | 1990 |
|
RU2008902C1 |
METHOD FOR TREATING PULMONARY TUBERCULOSIS AT PREDOMINANTLY PRODUCTIVE TYPE OF TISSUE REACTION | 2000 |
|
RU2204409C2 |
AGENT ENHANCING EFFECTIVENESS OF TREATMENT OF PATIENTS WITH TUBERCULOSIS | 1996 |
|
RU2136276C1 |
5-FLUORO-2-(4-ETHOXYCARBONYLDIPIPERAZINE-1-YL)-1,3-BENZOTHIAZINE-4-ONE, WHICH HAS ANTI-TUBERCULOSIS ACTIVITY | 2018 |
|
RU2663848C1 |
Authors
Dates
2000-07-27—Published
1998-12-04—Filed